PMC:7253233 / 2649-4886 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T12","span":{"begin":465,"end":487},"obj":"Body_part"},{"id":"T13","span":{"begin":489,"end":492},"obj":"Body_part"},{"id":"T14","span":{"begin":890,"end":896},"obj":"Body_part"},{"id":"T15","span":{"begin":999,"end":1004},"obj":"Body_part"},{"id":"T16","span":{"begin":1261,"end":1280},"obj":"Body_part"},{"id":"T17","span":{"begin":1564,"end":1569},"obj":"Body_part"},{"id":"T18","span":{"begin":2129,"end":2134},"obj":"Body_part"}],"attributes":[{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma55675"},{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma55675"},{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma32558"},{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma67498"},{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma265580"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma50801"},{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma50801"}],"text":"Introduction\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged first in Wuhan, China, in 2019 and spread rapidly worldwide as a pandemic of the twenty-first century. The symptoms and disease manifestations caused by SARS-CoV-2 were named Coronavirus disease 2019 (COVID-19) by the World Health Organization [1]. The neurological manifestations of this disease are not well known, and there is growing evidence that the disease has effects on the central nervous system (CNS) as detailed in retrospective reports from several centers worldwide. An initial retrospective case series from Wuhan, China, showed that neurological manifestations are present in patients with COVID-19 disease [2]. In that series, 45.5% of patients with COVID-19 disease who had severe systemic disease burden also suffered from acute cerebrovascular disease, acute encephalopathy, and skeletal muscle symptoms. These patients also had higher levels of inflammatory markers and greater evidence of multi-organ failure. However, the study did not elucidate how many patients with encephalopathy were monitored and treated for acute symptomatic seizures. Another series of patients were reported in Strasbourg, France, with neurological features of encephalopathy and corticospinal tract signs. Only a small proportion of the patients (8 out of 64) had electroencephalography performed, which demonstrated diffuse slowing consistent with encephalopathy [3]. Seizures have not been directly reported as a part of COVID-19 disease outside of patients with previously known brain injury or epilepsy.\nThere are several barriers to electrographically monitoring patients with SARS-CoV-2 infection such as prone positioning for respiratory compromise as well as the contamination risk which obviates a need for minimizing procedures in this patient population. Neurointensivists and neurologists are often consulted for severe COVID-19 patients that present with neurological features. In this report, we describe two patients who were electrographically monitored for acute encephalopathy and seizure-like activity, in the setting of normal brain imaging and who were found to have acute symptomatic seizures associated with severe COVID-19 disease."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T13","span":{"begin":465,"end":487},"obj":"Body_part"},{"id":"T14","span":{"begin":473,"end":487},"obj":"Body_part"},{"id":"T15","span":{"begin":489,"end":492},"obj":"Body_part"},{"id":"T16","span":{"begin":999,"end":1004},"obj":"Body_part"},{"id":"T17","span":{"begin":1261,"end":1280},"obj":"Body_part"},{"id":"T18","span":{"begin":1564,"end":1569},"obj":"Body_part"},{"id":"T19","span":{"begin":2129,"end":2134},"obj":"Body_part"}],"attributes":[{"id":"A13","pred":"uberon_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/UBERON_0001017"},{"id":"A14","pred":"uberon_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/UBERON_0001016"},{"id":"A15","pred":"uberon_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/UBERON_0001017"},{"id":"A16","pred":"uberon_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"},{"id":"A17","pred":"uberon_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/UBERON_0002707"},{"id":"A18","pred":"uberon_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"A19","pred":"uberon_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/UBERON_0000955"}],"text":"Introduction\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged first in Wuhan, China, in 2019 and spread rapidly worldwide as a pandemic of the twenty-first century. The symptoms and disease manifestations caused by SARS-CoV-2 were named Coronavirus disease 2019 (COVID-19) by the World Health Organization [1]. The neurological manifestations of this disease are not well known, and there is growing evidence that the disease has effects on the central nervous system (CNS) as detailed in retrospective reports from several centers worldwide. An initial retrospective case series from Wuhan, China, showed that neurological manifestations are present in patients with COVID-19 disease [2]. In that series, 45.5% of patients with COVID-19 disease who had severe systemic disease burden also suffered from acute cerebrovascular disease, acute encephalopathy, and skeletal muscle symptoms. These patients also had higher levels of inflammatory markers and greater evidence of multi-organ failure. However, the study did not elucidate how many patients with encephalopathy were monitored and treated for acute symptomatic seizures. Another series of patients were reported in Strasbourg, France, with neurological features of encephalopathy and corticospinal tract signs. Only a small proportion of the patients (8 out of 64) had electroencephalography performed, which demonstrated diffuse slowing consistent with encephalopathy [3]. Seizures have not been directly reported as a part of COVID-19 disease outside of patients with previously known brain injury or epilepsy.\nThere are several barriers to electrographically monitoring patients with SARS-CoV-2 infection such as prone positioning for respiratory compromise as well as the contamination risk which obviates a need for minimizing procedures in this patient population. Neurointensivists and neurologists are often consulted for severe COVID-19 patients that present with neurological features. In this report, we describe two patients who were electrographically monitored for acute encephalopathy and seizure-like activity, in the setting of normal brain imaging and who were found to have acute symptomatic seizures associated with severe COVID-19 disease."}

LitCovid-PD-MONDO

LitCovid-PD-CLO

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T20","span":{"begin":855,"end":875},"obj":"Phenotype"},{"id":"T21","span":{"begin":1074,"end":1088},"obj":"Phenotype"},{"id":"T22","span":{"begin":1126,"end":1146},"obj":"Phenotype"},{"id":"T23","span":{"begin":1242,"end":1256},"obj":"Phenotype"},{"id":"T24","span":{"begin":1431,"end":1445},"obj":"Phenotype"},{"id":"T25","span":{"begin":1451,"end":1459},"obj":"Phenotype"},{"id":"T26","span":{"begin":1580,"end":1588},"obj":"Phenotype"},{"id":"T27","span":{"begin":2056,"end":2076},"obj":"Phenotype"},{"id":"T28","span":{"begin":2081,"end":2088},"obj":"Phenotype"},{"id":"T29","span":{"begin":2176,"end":2196},"obj":"Phenotype"}],"attributes":[{"id":"A20","pred":"hp_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/HP_0006846"},{"id":"A21","pred":"hp_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/HP_0001298"},{"id":"A22","pred":"hp_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/HP_0011145"},{"id":"A23","pred":"hp_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/HP_0001298"},{"id":"A24","pred":"hp_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/HP_0001298"},{"id":"A25","pred":"hp_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/HP_0001250"},{"id":"A26","pred":"hp_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/HP_0001250"},{"id":"A27","pred":"hp_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/HP_0006846"},{"id":"A28","pred":"hp_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/HP_0001250"},{"id":"A29","pred":"hp_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/HP_0011145"}],"text":"Introduction\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged first in Wuhan, China, in 2019 and spread rapidly worldwide as a pandemic of the twenty-first century. The symptoms and disease manifestations caused by SARS-CoV-2 were named Coronavirus disease 2019 (COVID-19) by the World Health Organization [1]. The neurological manifestations of this disease are not well known, and there is growing evidence that the disease has effects on the central nervous system (CNS) as detailed in retrospective reports from several centers worldwide. An initial retrospective case series from Wuhan, China, showed that neurological manifestations are present in patients with COVID-19 disease [2]. In that series, 45.5% of patients with COVID-19 disease who had severe systemic disease burden also suffered from acute cerebrovascular disease, acute encephalopathy, and skeletal muscle symptoms. These patients also had higher levels of inflammatory markers and greater evidence of multi-organ failure. However, the study did not elucidate how many patients with encephalopathy were monitored and treated for acute symptomatic seizures. Another series of patients were reported in Strasbourg, France, with neurological features of encephalopathy and corticospinal tract signs. Only a small proportion of the patients (8 out of 64) had electroencephalography performed, which demonstrated diffuse slowing consistent with encephalopathy [3]. Seizures have not been directly reported as a part of COVID-19 disease outside of patients with previously known brain injury or epilepsy.\nThere are several barriers to electrographically monitoring patients with SARS-CoV-2 infection such as prone positioning for respiratory compromise as well as the contamination risk which obviates a need for minimizing procedures in this patient population. Neurointensivists and neurologists are often consulted for severe COVID-19 patients that present with neurological features. In this report, we describe two patients who were electrographically monitored for acute encephalopathy and seizure-like activity, in the setting of normal brain imaging and who were found to have acute symptomatic seizures associated with severe COVID-19 disease."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T26","span":{"begin":0,"end":12},"obj":"Sentence"},{"id":"T27","span":{"begin":13,"end":184},"obj":"Sentence"},{"id":"T28","span":{"begin":185,"end":330},"obj":"Sentence"},{"id":"T29","span":{"begin":331,"end":562},"obj":"Sentence"},{"id":"T30","span":{"begin":563,"end":709},"obj":"Sentence"},{"id":"T31","span":{"begin":710,"end":906},"obj":"Sentence"},{"id":"T32","span":{"begin":907,"end":1013},"obj":"Sentence"},{"id":"T33","span":{"begin":1014,"end":1147},"obj":"Sentence"},{"id":"T34","span":{"begin":1148,"end":1287},"obj":"Sentence"},{"id":"T35","span":{"begin":1288,"end":1450},"obj":"Sentence"},{"id":"T36","span":{"begin":1451,"end":1589},"obj":"Sentence"},{"id":"T37","span":{"begin":1590,"end":1847},"obj":"Sentence"},{"id":"T38","span":{"begin":1848,"end":1972},"obj":"Sentence"},{"id":"T39","span":{"begin":1973,"end":2237},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Introduction\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged first in Wuhan, China, in 2019 and spread rapidly worldwide as a pandemic of the twenty-first century. The symptoms and disease manifestations caused by SARS-CoV-2 were named Coronavirus disease 2019 (COVID-19) by the World Health Organization [1]. The neurological manifestations of this disease are not well known, and there is growing evidence that the disease has effects on the central nervous system (CNS) as detailed in retrospective reports from several centers worldwide. An initial retrospective case series from Wuhan, China, showed that neurological manifestations are present in patients with COVID-19 disease [2]. In that series, 45.5% of patients with COVID-19 disease who had severe systemic disease burden also suffered from acute cerebrovascular disease, acute encephalopathy, and skeletal muscle symptoms. These patients also had higher levels of inflammatory markers and greater evidence of multi-organ failure. However, the study did not elucidate how many patients with encephalopathy were monitored and treated for acute symptomatic seizures. Another series of patients were reported in Strasbourg, France, with neurological features of encephalopathy and corticospinal tract signs. Only a small proportion of the patients (8 out of 64) had electroencephalography performed, which demonstrated diffuse slowing consistent with encephalopathy [3]. Seizures have not been directly reported as a part of COVID-19 disease outside of patients with previously known brain injury or epilepsy.\nThere are several barriers to electrographically monitoring patients with SARS-CoV-2 infection such as prone positioning for respiratory compromise as well as the contamination risk which obviates a need for minimizing procedures in this patient population. Neurointensivists and neurologists are often consulted for severe COVID-19 patients that present with neurological features. In this report, we describe two patients who were electrographically monitored for acute encephalopathy and seizure-like activity, in the setting of normal brain imaging and who were found to have acute symptomatic seizures associated with severe COVID-19 disease."}

2_test

{"project":"2_test","denotations":[{"id":"32462412-32257431-75539777","span":{"begin":327,"end":328},"obj":"32257431"},{"id":"32462412-32453517-75539778","span":{"begin":1447,"end":1448},"obj":"32453517"}],"text":"Introduction\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged first in Wuhan, China, in 2019 and spread rapidly worldwide as a pandemic of the twenty-first century. The symptoms and disease manifestations caused by SARS-CoV-2 were named Coronavirus disease 2019 (COVID-19) by the World Health Organization [1]. The neurological manifestations of this disease are not well known, and there is growing evidence that the disease has effects on the central nervous system (CNS) as detailed in retrospective reports from several centers worldwide. An initial retrospective case series from Wuhan, China, showed that neurological manifestations are present in patients with COVID-19 disease [2]. In that series, 45.5% of patients with COVID-19 disease who had severe systemic disease burden also suffered from acute cerebrovascular disease, acute encephalopathy, and skeletal muscle symptoms. These patients also had higher levels of inflammatory markers and greater evidence of multi-organ failure. However, the study did not elucidate how many patients with encephalopathy were monitored and treated for acute symptomatic seizures. Another series of patients were reported in Strasbourg, France, with neurological features of encephalopathy and corticospinal tract signs. Only a small proportion of the patients (8 out of 64) had electroencephalography performed, which demonstrated diffuse slowing consistent with encephalopathy [3]. Seizures have not been directly reported as a part of COVID-19 disease outside of patients with previously known brain injury or epilepsy.\nThere are several barriers to electrographically monitoring patients with SARS-CoV-2 infection such as prone positioning for respiratory compromise as well as the contamination risk which obviates a need for minimizing procedures in this patient population. Neurointensivists and neurologists are often consulted for severe COVID-19 patients that present with neurological features. In this report, we describe two patients who were electrographically monitored for acute encephalopathy and seizure-like activity, in the setting of normal brain imaging and who were found to have acute symptomatic seizures associated with severe COVID-19 disease."}

PMC:7253233 / 2649-4886 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7253233 / 2649-4886 JSON TXT